- Home
- Products
- Customized FluoroAb™
- ERBB2
- Margetuximab-iFluor 555
Margetuximab-iFluor 555 (CAT#: ADC-FL-1356)
This product is comprised of an anti-ERBB2 monoclonal antibody (Margetuximab) labeled with iFluor 555. iFluor 555 is a fluorescent dye and it's excitation/emission is 555/580 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Chimeric Anti-ERBB2 IgG1-kappa antibody,Margetuximab
- Generic name
- Margetuximab
- Species Reactivity
- Human
- Name
- iFluor 555
- Excitation⁄Emission (nm)
- 555/580
- Detection method
- Fluorescent
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EGFR MAb (Clone 20)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5460)
- Anti-ITGAL MAb (Clone 1)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS648)
- Otlertuzumab-iFluor 680 (CAT#: ADC-FL-514)
- Anti-TAG-72 MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5368)
- Anti-HBV surface antigen MAb (Clone 2)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16940)
- Toralizumab-Fluoresein (CAT#: ADC-FL-808)
- Anti-C5 MAb (Clone 3)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11596)
- Anti-MUC1 MAb (Clone 3)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3427)
- Anti-IL4R MAb (Clone 1)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3709)
- Anti-CSF1R MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS3183)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-FL-1356. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-514 | Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC | VC (valine-citrulline) | seco-DUBA (DUocarmycin hydroxyBenzamide Azaindole) |
| ADC-W-1110 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1117 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.